to evaluate the long-term survival and clinicopathologic factors in pts after treatment for MOGCT.
A total of 163 pts treated for MOGCT in our center between 1987-2015 were included into this retrospective study. Clinical data including symptoms, demographics, stage, surgery, chemotherapy, survival were collected from medical records and assessed in univariate analysis.
The median age was 21 years (range, 12-49 years). 109 (66.9%) of 163 underwent fertility-preserving surgery followed by chemotherapy. Histologically (n = 159) 27.7% of cases were pure dysgerminoma, in 4 pts histologic data were not available. 129 (79%) pts received BEP regimen as a first line treatment, and 34 (20.9%) treated with other regimens. 13 (8%) pts had gonadal dysgenesis. With median follow-up of 88 month (range 1-337 month) 10-year OS was 84% and 48 (29.4%) pts had disease recurrence. The 5-year disease free survival in pts with dysgerminoma and non-dysgerminoma was 87% and 66% respectively (HR 0.45, p = .04). BEP regimen was significantly superior to non-BEP regimen in 10-year OS (94% vs 55%, HR 7.1, p
Comprehensive surgical staging was associated with a lower rate of recurrence. Pts with negative prognostic factors perhaps need more aggressive therapy. It requires additional studies for improvement of therapeutic strategy.
Clinical trial identification
Legal entity responsible for the study
Budget of clinic
All authors have declared no conflicts of interest.